Threshold
Pharmaceuticals, Inc. THLD, today announced early data from
the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of
its investigational hypoxia-targeted drug TH-302 in combination with
Avastin(R) (bevacizumab) in patients with recurrent glioblastoma
following bevacizumab failure (Study 4003). No dose-limiting toxicity
has been reported to date at doses of TH-302 up to 670 mg/m2 plus
bevacizumab at 10 mg/m2 every two weeks. Preliminary data in 14
patients showed TH-302 in combination with bevacizumab was associated
with a median time to progression of 2.8 months. One patient achieved
a complete response and two patients achieved partial responses. The
data will be presented this evening from 7 p.m. to 9 p.m. at the 4th
Quadrennial World Federation of Neuro-Oncology (WFNO) meeting held in
conjunction with the 18th annual 2013 Scientific Meeting and
Education Day of the Society for Neuro-Oncology (SNO), San Francisco,
CA.
Chemotherapy with radiotherapy is standard care for newly diagnosed
glioblastoma. Bevacizumab is approved in the U.S. for progressive
disease following prior therapy. After disease progression on
bevacizumab, patients may start a subsequent bevacizumab-containing
regimen. These patients typically progress in 5 to 8 weeks.(1,2)
Three-month progression-free survival is approximately 15%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in